Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

FDA Approves Aficamten for Obstructive HCM

L.A. McKeown

December 29, 2025

Presentation TCT 2025

TCT 563: Comparative Outcomes of Mavacamten with AV Nodal Blockers vs. AV Nodal Blockers Alone in Patients with Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Presenter: Aditya Desai

October 28, 2025

Presentation ESC 2025

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Presenter: Milind Y Desai

August 30, 2025

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Caitlin E. Cox

August 30, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2025

Caitlin E. Cox

April 30, 2025

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

L.A. McKeown

April 15, 2025

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Daily News

Aficamten Delivers Positive Results in SEQUOIA-HCM

Todd Neale

December 27, 2023

Podcast TCTMD Talking Points

The VALOR-HCM Trial

August 02, 2023

Podcast TCTMD Talking Points

MAVA-LTE: The EXPLORER-LTE Cohort

April 19, 2023

News Daily News

Top Heart Failure News of 2022

Shelley Wood

January 04, 2023

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Advertisement

FDA Approves Aficamten for Obstructive HCM

TCT 563: Comparative Outcomes of Mavacamten with AV Nodal Blockers vs. AV Nodal Blockers Alone in Patients with Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

What’s Going to Be Hot at ESC Congress 2025?

TCTMD’s Top 10 Most Popular Stories for April 2025

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

Top Heart Failure News of 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Aficamten Delivers Positive Results in SEQUOIA-HCM

The VALOR-HCM Trial

MAVA-LTE: The EXPLORER-LTE Cohort

Top Heart Failure News of 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content